SCHEMBL5012322

SCHEMBL5012322

O=C(O)c1ccc2c(c1)C(=O)N(c1ccc(F)cc1)C2=O

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 7/20 0.68
CA1 P00915 6/20 0.68
CA2 P00918 3/20 0.68
CA4 P22748 3/20 0.68
KMT2A Q03164 3/20 0.66
MEN1 O00255 2/20 0.66
GFER P55789 1/20 0.66
NPSR1 Q6W5P4 2/20 0.65
CA12 O43570 6/20 0.64
SCN2A Q99250 1/20 0.61
POLB P06746 3/20 0.59
ALDH1A1 P00352 2/20 0.59
MAPT P10636 1/20 0.59
RAB9A P51151 1/20 0.59
HPGD P15428 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
PTGER4 P35408 1/20 0.55
HSD17B10 Q99714 1/20 0.54
CA7 P43166 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9339007 0.92 CA9 (0.77) CA9CA1CA2CA4KMT2A
SCHEMBL4234750 0.90 CA9 (0.77) CA9CA1CA2CA4KMT2A
SCHEMBL9742475 0.87 CA9 (0.71) CA9CA1CA2CA4KMT2A
SCHEMBL5010584 0.86 CA9 (0.85) CA9CA1CA2CA4KMT2A
SCHEMBL8066756 0.86 ESR1 (0.70) CA9CA1CA2CA4KMT2A
SCHEMBL1618163 0.85 KMT2A (0.76) CA9CA1CA2CA4KMT2A
SCHEMBL22523866 0.84 CA9 (0.68) CA9CA1CA2CA4KMT2A
SCHEMBL4725618 0.84 CA9 (0.69) CA9CA1CA2CA4KMT2A
SCHEMBL5013757 0.84 HSD17B10 (0.64) CA9CA1CA2CA4KMT2A
SCHEMBL9564296 0.83 CA9 (0.66) CA9CA1CA2CA4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319098-B2 1,3-dioxoisoindole derivatives having selective antagonism of T-type calcium channel KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2008-01-15 US disclosed
US-20070259867-A1 1,3-DIOXOISOINDOLE DERIVATIVES HAVING SELECTIVE ANTAGONISM OF T-TYPE CALCIUM CHANNEL KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259867-A1 1,3-DIOXOISOINDOLE DERIVATIVES HAVING SELECTIVE ANTAGONISM OF T-TYPE CALCIUM CHANNEL CACNA1I, CACNA1G, CACNA1H CA9 1757/4885CA1 636/4885CA2 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.